A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
Launched by MASSACHUSETTS GENERAL HOSPITAL · Feb 8, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to see which of two educational programs helps people with Neurofibromatosis 1 (NF1) get better health screenings during their regular doctor visits. NF1 is a genetic condition that can cause skin changes and other health issues. The study aims to help patients understand the importance of these screenings, especially those who may not have access to specialized clinics.
To be eligible for the trial, participants must either be adults with a diagnosis of NF1 living in the U.S. or parents/guardians of children with NF1. They should not be visiting a specialized NF clinic and must have an upcoming wellness visit with their primary care doctor within three months. Participants can expect to receive information about their health and the study will help determine which educational approach works best. It's important to know that only one person from each household can join the study, and participants need to be comfortable giving their consent to take part.
Gender
ALL
Eligibility criteria
- Adult Inclusion Criteria:
- • Currently lives in the United States (including Puerto Rico and other United States territories)
- • Has a clinical diagnosis of neurofibromatosis 1
- • Does not attend an NF clinic within the Children's Tumor Foundation NF Clinic Network
- • Has an in-person, well-person visit with a primary care provider scheduled within 3 months of their consent
- • Speaks English or Spanish
- Parent/Guardian of a Child with NF1 Inclusion Criteria:
- • Currently lives in the United States (including Puerto Rico and other United States territories)
- • Cares for a child (age \<18 years) with a clinical diagnosis of neurofibromatosis 1
- • Does not attend an NF clinic within the Children's Tumor Foundation NF Clinic Network
- • Their child has an in-person, well-person visit with a primary care provider scheduled within 3 months of their consent
- • Speaks English or Spanish
- Exclusion Criteria:
- • Only one person per household may participate in the study
- • Unwilling or unable to give informed consent
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Vanessa Merker, PhD
Principal Investigator
Massachusetts General Hospital
Scott Plotkin, MD, PhD
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported